Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,528 | -13,977 | -6,719 | -27,808 | -20,675 |
| Depreciation Amortization | 37 | 37 | 26 | 459 | 418 |
| Accounts payable and accrued liabilities | 511 | 311 | 340 | -250 | 51 |
| Other Working Capital | 337 | -90 | -726 | 914 | 2,331 |
| Other Operating Activity | 1,370 | 1,179 | 698 | 2,557 | 1,578 |
| Operating Cash Flow | $-19,273 | $-12,540 | $-6,381 | $-24,128 | $-16,297 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -25,289 | -12,431 | 0 | N/A | 0 |
| PPE Investments | -298 | -295 | -102 | -251 | -210 |
| Investing Cash Flow | $-25,587 | $-12,726 | $-102 | $-251 | $-210 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | 0 | 0 | -80 | -81 |
| Common Stock Issued | 4,491 | 2 | 2 | 53,817 | 21,411 |
| Financing Cash Flow | $4,491 | $2 | $2 | $53,737 | $21,330 |
| Beginning Cash Position | 60,445 | 60,445 | 60,445 | 31,087 | 31,087 |
| End Cash Position | 20,076 | 35,181 | 53,964 | 60,445 | 35,910 |
| Net Cash Flow | $-40,369 | $-25,264 | $-6,481 | $29,358 | $4,823 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,273 | -12,540 | -6,381 | -24,128 | -16,297 |
| Capital Expenditure | -298 | -295 | -102 | -251 | -210 |
| Free Cash Flow | -19,571 | -12,835 | -6,483 | -24,379 | -16,507 |